Literature DB >> 3465381

Immunological detection and quantitation of alpha transforming growth factors in human breast carcinoma cells.

I Perroteau, D Salomon, M DeBortoli, W Kidwell, P Hazarika, R Pardue, J Dedman, J Tam.   

Abstract

Alpha transforming growth factors (alpha TGFs) were immunologically detected in the concentrated conditioned medium (CM) prepared from four human breast cancer cell lines and from primary cultures of human mammary epithelial cells, and in the tissue extracts prepared from normal, benign, and malignant breast biopsies. Immunoreactive alpha TGFs were quantitated by a competitive radioimmunoassay (RIA) using affinity-purified polyclonal sheep anti-rat alpha TGF antibodies which react with human alpha TGF but not with human epidermal growth factor (EGF). The relative level of RIA-detectable alpha TGFs in the CM from the breast cancer cell lines MCF-7, ZR-75-1, T47-D, and MDA-MB-231, and from the CM of primary cultures of human mammary epithelial cells, ranged from 0.02 to 0.85 ng/ml. MCF-7 or ZR-75-1 cells grown in the presence of 17 beta-estradiol (10(-8) M) for 48 h were found to release two- to three-fold more alpha TGFs into their CM than the same cells grown in the absence of estrogen. In detergent extracts prepared from normal breast tissue, a benign fibrocystic lesion, fibroadenomas and primary breast carcinomas, the relative alpha TGF concentrations were found to range from 1.5 to 6 ng/mg cell protein. No significant correlations were found between the alpha TGF levels and the pathological state of the tissues, the estrogen receptor status of the tumors, or the relative amounts of the ras gene protein p21ras in the tissues as determined by Western immunoblot analysis. The question of biological relevancy of alpha TGF for human mammary tumors will require further studies on synthesis and turnover of alpha TGF, the relationship between immunoreactivity and biological activity of alpha TGF, and differences in biological responsiveness of mammary tumor cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3465381     DOI: 10.1007/BF01806251

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  Detection of larger polypeptides structurally and functionally related to type I transforming growth factor.

Authors:  P S Linsley; W R Hargreaves; D R Twardzik; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

2.  Partial purification of transforming growth factors from human milk.

Authors:  J A Zwiebel; M Bano; E Nexo; D S Salomon; W R Kidwell
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

3.  Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.

Authors:  P H Hand; A Thor; D Wunderlich; R Muraro; A Caruso; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

4.  Anchorage-independent growth-conferring factor production by rat mammary tumor cells.

Authors:  J A Zwiebel; M R Davis; E Kohn; D S Salomon; W R Kidwell
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

5.  Synthesis and secretion of an epidermal growth factor (EGF) by human fibroblast cells in culture.

Authors:  M Kurobe; S Furukawa; K Hayashi
Journal:  Biochem Biophys Res Commun       Date:  1985-09-30       Impact factor: 3.575

6.  Distinct high-performance liquid chromatography pattern of transforming growth factor activity in urine of cancer patients as compared with that of normal individuals.

Authors:  E S Kimball; W H Bohn; K D Cockley; T C Warren; S A Sherwin
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

7.  Cellular transformation by coordinated action of three peptide growth factors from human platelets.

Authors:  R K Assoian; G R Grotendorst; D M Miller; M B Sporn
Journal:  Nature       Date:  1984 Jun 28-Jul 4       Impact factor: 49.962

8.  Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels.

Authors:  S L Fitzpatrick; J Brightwell; J L Wittliff; G H Barrows; G S Schultz
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

9.  Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents.

Authors:  M E DeBortoli; H Abou-Issa; B E Haley; Y S Cho-Chung
Journal:  Biochem Biophys Res Commun       Date:  1985-03-15       Impact factor: 3.575

10.  Secretion of transforming growth factors by primary human tumour cells.

Authors:  A W Hamburger; C P White; F E Dunn
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

View more
  17 in total

1.  Structure-function analysis of human transforming growth factor-alpha by site-directed mutagenesis.

Authors:  J A Feild; R H Reid; D J Rieman; T P Kline; G Sathe; R G Greig; M A Anzano
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.

Authors:  M Alimandi; L M Wang; D Bottaro; C C Lee; A Kuo; M Frankel; P Fedi; C Tang; M Lippman; J H Pierce
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

Review 3.  Incidence and pathophysiology of hypercalcemia.

Authors:  G R Mundy
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

4.  Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells.

Authors:  N E Hynes; D Taverna; I M Harwerth; F Ciardiello; D S Salomon; T Yamamoto; B Groner
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

5.  Gastrin releasing peptide GRP(14-27) in human breast cancer cells and in small cell lung cancer.

Authors:  A J Vangsted; E V Andersen; L Nedergaard; J Zeuthen
Journal:  Breast Cancer Res Treat       Date:  1991-10       Impact factor: 4.872

6.  Growth of MTW9/PL2 estrogen-responsive rat mammary tumor cells in hormonally defined serum-free media.

Authors:  D Danielpour; T L Riss; M Ogasawara; D A Sirbasku
Journal:  In Vitro Cell Dev Biol       Date:  1988-01

7.  A 23-pS Ca2(+)-activated K+ channel in MCF-7 human breast carcinoma cells: an apparent correlation of channel incidence with the rate of cell proliferation.

Authors:  E A Wegman; J A Young; D I Cook
Journal:  Pflugers Arch       Date:  1991-02       Impact factor: 3.657

8.  Epidermal growth factor-like activity and epidermal growth factor-receptors in human primary breast cancer.

Authors:  Z Kahán; M Szücs; M Vecsernyés; S Eckhardt
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Transforming growth factor-alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells.

Authors:  G H Smith; R Sharp; E C Kordon; C Jhappan; G Merlino
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

Review 10.  Biology of pancreatic cancer.

Authors:  G J Poston; J Gillespie; P J Guillou
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.